Considering all that CHM already got achieved and confirmed by the trial data the MC should be at least at 200m, about 30c. But for a strange reason the market values CHM at 25m including about at least 10m cash while ALA is valued at 135m including about 15m cash due to CR. ALA hasn't even managed to get an IND, delays and a terminated co-op by IMU and yet, for having nothing to show for, it has become a market darling.
That's the problem in AUS, you got something fantastic - you will be devalued. Got nothing - you get $$$$ thrown at you. Must be the Southern Hemisphere I think.
GLTA
Ann: Clinical milestones for 2024 & 2023 successes highlighted, page-27
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.002(11.1%) |
Mkt cap ! $17.25M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.1¢ | 1.9¢ | $56.44K | 2.801M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1655923 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 1520755 | 2 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CHM (ASX) Chart |